MD |PCCM Fellow | Former Chief | Opinions ≠ Medical Advice | #EBMfanatic #Barcaforlife #TheNorth
Apr 15, 2019 • 7 tweets • 5 min read
nejm.org/doi/full/10.10…#LastWeekOnNEJM We reviewed the ANNEXA-4 Trial @AHNtoday for #AHNIMRes This trial was conducted to show the effectiveness of Andexanet Alfa as a reversal agent for major bleeds caused by Factor Xa inhibitors @TKapetanos@NEJM@KaminskiMed@Rick_Pescatore
Andexanet alfa is a modified inactive form of human factor Xa designed to bind and sequester factor Xa inhibitor molecules, thereby rapidly reducing anti-factor Xa molecules and activity